A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Conditions
Interventions
- BIOLOGICAL: Certolizumab Pegol
- OTHER: Placebo
- BIOLOGICAL: Methotrexate
Sponsor
UCB Pharma SA